Zhang Ya-Jie, Wu Meng-Jun, Li Yi, Yu Hai
Department of Anesthesiology and Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
Department of Anesthesiology and Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
Med Hypotheses. 2015 Jan;84(1):20-4. doi: 10.1016/j.mehy.2014.11.008. Epub 2014 Nov 17.
Although improvement in cardiopulmonary resuscitation (CPR) performance and the increasing success at achieving return of spontaneous circulation (ROSC) have been possible in recent years, the survival and discharge rates of post-cardiac arrest (CA) patients remain disappointing. The high mortality rate is attributed to whole-body ischemia/reperfusion (I/R) induced multi-organ dysfunction that is well known as post-cardiac arrest syndrome. Post-cardiac arrest myocardial dysfunction and brain injury are the main clinical features of this complex pathophysiological process. Previous evidences have shown that volatile anesthetics, such as isoflurane, trigger a powerful and highly integrated cell survival response during I/R period in multiple organs, including heart and brain, which reduces I/R injury. This effect that called anesthetic-induced postconditioning can be shown when volatile anesthetics are administered after the onset of ischemia and at the time of reperfusion. Emulsified isoflurane (EIso) is a new anesthetic for intravenous administration, which is conveniently feasible outside operating room. Therefore, we hypothesize that EIso postconditioning could provide the cardiocerebral protection, and combined with therapeutic hypothermia as sedative agent could produce enhanced cardiocerebral protection, which can result in significant improvement of neurologically intact post-cardiac arrest survival. We consider that it would become a feasible, safe and efficient cardiocerebral protective intervention in the prevention and alleviation of post-cardiac arrest syndrome, which would also improve the outcomes after CA.
尽管近年来心肺复苏(CPR)操作有所改进,实现自主循环恢复(ROSC)的成功率也有所提高,但心脏骤停(CA)后患者的生存率和出院率仍然令人失望。高死亡率归因于全身缺血/再灌注(I/R)诱导的多器官功能障碍,即众所周知的心脏骤停后综合征。心脏骤停后心肌功能障碍和脑损伤是这一复杂病理生理过程的主要临床特征。先前的证据表明,挥发性麻醉剂,如异氟烷,在包括心脏和大脑在内的多个器官的I/R期间触发强大且高度整合的细胞存活反应,从而减少I/R损伤。当在缺血开始后和再灌注时给予挥发性麻醉剂时,可以显示出这种称为麻醉诱导后处理的效果。乳化异氟烷(EIso)是一种新型静脉麻醉剂,在手术室之外使用方便可行。因此,我们假设EIso后处理可以提供心脑保护,并且与治疗性低温联合作为镇静剂可以产生增强的心脑保护作用,这可以显著提高心脏骤停后神经功能完好的生存率。我们认为,这将成为一种可行、安全且有效的心脑保护干预措施,用于预防和减轻心脏骤停后综合征,这也将改善CA后的预后。